A Phase I Study of NVL-520 in People with Solid Tumors


Full Title

A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)


The purpose of this study is to find the highest dose of the investigational drug NVL-520 that can be given safely in people with metastatic solid tumors that contain a change (fusion) involving the ROS1 gene. A fusion gene is made when parts of two different genes join together. NVL-520 blocks the ROS1 protein, which promotes cancer cell growth and survival. It is taken orally (by mouth

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have a metastatic solid tumor that has an ROS1 fusion, such as non-small cell lung cancer.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Alexander Drilon at 646-608-3758.




Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID